Catalog No.
Product Name
Application
Product Information
Citations
-
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-39 is a targeted PROTAC that effectively degrades the EZH2 protein, exhibiting an IC50 of 61.00 nM. This compound functionally inhibits the methyltransferase activity of EZH2, making it an important tool for studying the biological implications of EZH2 modulation. Its applications include cancer research and epigenetic regulation studies, contributing to advancements in targeted therapy development. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-15 is a targeted degrader that specifically interacts with the EZH2 protein via a proteolysis-targeting chimera (PROTAC) mechanism. This compound effectively inhibits the methyltransferase activity of EZH2, leading to its degradation and resulting in alterations to histone methylation patterns. It serves as a valuable tool for research applications focused on epigenetic regulation, cancer biology, and therapeutic strategies aimed at EZH2 modulated pathways. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-10 is a Proteolysis Targeting Chimeras (PROTAC) compound designed to selectively degrade the enhancer of zeste homolog 2 (EZH2). By facilitating the ubiquitination and subsequent proteasomal degradation of EZH2, this compound exhibits potential as an innovative therapeutic approach for cancer research. Its mechanism involves a specific ligand for EZH2 and a cereblon ligand, linked together to enhance degradation efficiency, making it a valuable tool for investigating EZH2-related oncogenic pathways. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-35 is a proteolysis-targeting chimera (PROTAC) specifically designed to degrade the Enhancer of Zeste Homolog 2 (EZH2) protein, exhibiting a binding affinity (Ka) of 16.19 nM. This compound demonstrates significant antiproliferative activity against triple-negative breast cancer cells while maintaining minimal cytotoxicity toward normal human epithelial, hepatic, and renal cells. PROTAC EZH2 Degrader-35 is a valuable tool for studying the role of EZH2 in cancer biology and has potential applications in therapeutic research focused on triple-negative breast cancer. -
EZH2 PROTAC
PROTAC EZH2 Degrader-27 is a potent EZH2 PROTAC inhibitor with an IC50 of 4.00 nM, specifically designed to target the SET domain of the EZH2 methyltransferase. By engaging in targeted protein degradation, this compound effectively inhibits methyltransferase activity, leading to downregulation of histone methylation. Research applications include studies on epigenetic regulation and potential therapeutic strategies targeting EZH2 in various cancers. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-13 is a targeted proteolysis-targeting chimera (PROTAC) designed to selectively degrade Enhancer of Zeste Homolog 2 (EZH2) with an IC50 of 2.70 nM. This compound exhibits potent antiproliferative effects in various cancer cell lines, making it a valuable tool in cancer research. PROTAC EZH2 Degrader-13 facilitates investigations into the role of EZH2 in tumorigenesis and therapeutic resistance, providing insights for the development of innovative cancer treatments. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-23 is a targeted protein degradant that specifically degrades EZH2 through a PROTAC mechanism. It acts by inhibiting the methyltransferase activity of EZH2 via binding to the SET domain, exhibiting a target IC50 of 30.00 nM. This compound is valuable for research applications focused on the modulation of gene silencing pathways and the exploration of EZH2's role in cancer biology. -
PRMT5/MEP50 complex Degrader
MS115 is a selective degrader targeting the PRMT5/MEP50 complex, demonstrating DC50 values of 17.4 nM and 11.3 nM for PRMT5 at 24 hours in MDAMB468 breast cancer cells. This compound effectively inhibits the proliferation of breast cancer cells, making it a valuable tool for studying PRMT5-mediated pathways and evaluating therapeutic strategies in cancer research. MS115's unique mechanism positions it as a significant reagent for investigating the roles of epigenetic regulators in tumor biology. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-37 is a PROTAC compound designed to induce the degradation of the EZH2 protein, exhibiting a target IC50 of 144 nM. This reagent is valuable for research related to lymphomas and other conditions where dysregulation of histone methylation is implicated. Its mechanism harnesses the cellular degradation pathway, providing a potent tool for studying EZH2-dependent biological processes and developing therapeutic strategies against EZH2-driven malignancies. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-28 is a targeted PROTAC protein degrader designed to selectively degrade the EZH2 enzyme, demonstrating an IC50 of 16.2 μM in diffuse large B-cell lymphoma (DLBCL) cell lines. This compound is valuable for studying the role of EZH2 in lymphoma biology and therapeutic interventions. Its dual-ligand structure combines an EZH2 ligand with a VHL ligand, facilitating targeted protein degradation for advancing cancer research. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-20 is a small-molecule degrader specifically designed to target the EZH2 protein, utilizing the proteolysis targeting chimera (PROTAC) mechanism. It demonstrates potent antiproliferative effects with an IC50 of approximately 10 μM in lymphoma cell lines. This compound is ideal for research focused on understanding the role of EZH2 in lymphoma and exploring new therapeutic approaches for this malignancy. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-25 is a proteolysis-targeting chimera (PROTAC) designed to specifically degrade the EZH2 protein through targeted ubiquitination and proteasomal degradation. This compound is valuable for investigating the role of EZH2 in various lymphoma types, facilitating studies on its contribution to tumorigenesis. In addition, it illustrates the potential of PROTAC technology in modulating epigenetic regulators for therapeutic applications. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-16 is a targeted PROTAC protein degrader that specifically induces the degradation of EZH2, exhibiting an IC50 of 13.74 μM in SU-DHL-6 cells. This compound demonstrates significant antiproliferative activity against diffuse large B-cell lymphoma (DLBCL) cells, making it valuable for research focused on DLBCL. Its unique design incorporates a histone methyltransferase ligand and a Cereblon ligand linked via a proprietary linker, facilitating targeted degradation for therapeutic exploration. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-31 is a targeted protein degrader that effectively interacts with EZH2, promoting its degradation through the use of a PROTAC strategy. This compound demonstrates potent antiproliferative activity, with IC50 values of 3.63 μM in lSU-DHL-6 cells and 8.74 μM in HBL-1 cells. It is valuable for research focused on lymphoma, offering insights into EZH2-mediated pathways and potential therapeutic interventions. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-14 is an EZH2-targeting PROTAC degrader that selectively induces degradation of the EZH2 protein. With an IC50 of 18.21 μM, it effectively targets diffuse large B-cell lymphoma cells while showing no antiproliferative effects on non-target cells at concentrations up to 30.00 μM. This compound is valuable for research focused on the role of EZH2 in diffuse large B-cell lymphoma and provides a tool for exploring novel therapeutic strategies in oncology. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-22 is a PROTAC (Proteolysis Targeting Chimera) designed to target and degrade the EZH2 protein. This compound effectively modulates EZH2 activity, leading to the inhibition of histone methylation and promoting cancer cell apoptosis. It is particularly valuable in cancer-related research, facilitating the study of epigenetic regulation and therapeutic interventions. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-42 is a targeted degrader that specifically induces degradation of EZH2, a histone methyltransferase, via cIAP-mediated ubiquitination and subsequent proteasomal pathway. This compound exhibits antiproliferative activity and is particularly useful in the study of lymphoma. By modulating EZH2 levels, it provides a valuable tool for investigating epigenetic regulation and related therapeutic strategies in cancer research. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-36 is a targeted PROTAC designed to degrade the EZH2 protein, exhibiting a target IC50 of 16.00 nM. This compound is particularly relevant for research applications related to lymphoma, leveraging the selective degradation of EZH2 to investigate its role in cancer progression. The molecule consists of a histone methyltransferase ligand, a Cereblon ligand, and a linker, facilitating the ubiquitin-proteasome pathway for protein elimination. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-19 is a potent PROTAC compound that targets the enhancing zeste homolog 2 (EZH2) with an IC50 of 15.00 nM. This reagent effectively induces degradation of all Polycomb Repressive Complex 2 (PRC2) subunits, including EZH2, SUZ12, EED, and RbAp48, in a concentration- and time-dependent manner. PROTAC EZH2 Degrader-19 demonstrates significant antiproliferative effects in cancer cell lines, making it a valuable tool for cancer research and therapeutic applications. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-34 is a targeted degrader of EZH2, exhibiting an IC50 of 6.30 μM in human EZH2 inhibition. This compound is designed to selectively induce the degradation of EZH2, a key enzyme involved in histone methylation. Its applications are primarily in the study of malignancies such as Pfeiffer and prostate cancer, facilitating investigations into the molecular mechanisms of oncogenesis and potential therapeutic interventions. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-11 is a targeted protein degrader designed to selectively degrade the EZH2 protein through a PROTAC mechanism. This compound effectively reduces tumor size and viability in three-dimensional spheroid models, demonstrating potential for cancer research applications. The technology leverages a dual-ligand system, incorporating an EZH2 ligand and a Cereblon ligand, connected by a linker to facilitate the targeted degradation process. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-45 is a specialized PROTAC protein degrader designed to target EZH2, exhibiting an IC50 of 22.97 μM in SU-DHL-6 cells. This compound is primarily utilized in research focused on diffuse large B-cell lymphoma, providing insights into epigenetic regulation through targeted protein degradation. The product includes a histone methyltransferase ligand and a VHL ligand, linked for enhanced efficacy in cellular studies. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-40 is a PROTAC protein degrader specifically designed to target the enhancer of zeste homolog 2 (EZH2), exhibiting an IC50 value of 15.35 μM in SU-DHL-6 cells. This compound is valuable for researching diffuse large B-cell lymphoma and related epigenetic mechanisms. Its structure consists of a histone methyltransferase ligand, an aminopeptidase ligand, and a linker, facilitating targeted degradation of EZH2 to explore therapeutic potential in cancer treatment. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-29 is a targeted protein degrader that specifically engages the EZH2 protein, exhibiting an IC50 of 24.53 μM in diffuse large B-cell lymphoma cells. This compound serves as a valuable tool for investigating the degradation of EZH2 in both basic and translational research settings related to diffuse large B-cell lymphoma and other malignancies. -
METTL3-METTL14 Degrader
WD6305 is a selective PROTAC degrader targeting METTL3 and METTL14, with DC50 values of 140 nM and 194 nM, respectively. This compound effectively inhibits m6A modification and has been shown to suppress proliferation and induce apoptosis in acute myeloid leukemia (AML) cells. WD6305 demonstrates significant antitumor activity, making it a valuable tool for research on RNA modifications and cancer therapeutics. -
CRBN Degrader
WDR5 Degrader-1 is a cereblon (CRBN)-recruiting compound designed to selectively induce degradation of the WDR5 protein. This degrader effectively targets WDR5 while sparing the CRBN neo-substrate IKZF1, facilitating precise manipulation of WDR5 levels in cellular systems. It is a valuable tool for investigating the biological roles of WDR5 in transcriptional regulation and potential therapeutic strategies in diseases associated with dysregulated WDR5 expression. -
PROTAC WDR5 Degrader
XF067-68 is a PROTAC designed for the targeted degradation of the WD40 repeat domain protein 5 (WDR5). This compound facilitates the specific elimination of WDR5, making it a valuable tool for investigating diseases associated with WDR5 dysregulation. Researchers can employ XF067-68 to elucidate the biological roles of WDR5 and explore potential therapeutic interventions in related disorders. -
WDR5 Degrader
XF056-132 free base is a potent WDR5 (WD40 repeat domain protein 5) degrader that utilizes the proteolysis-targeting chimeric (PROTAC) mechanism. This compound effectively promotes the selective degradation of WDR5, which is implicated in various cancers and transcriptional regulation processes. XF056-132 serves as a valuable tool for research into targeted protein degradation and its therapeutic potential in oncological studies. -
WDR5 PROTAC Degrader
MS40 is a WDR5 PROTAC degrader with a Kd of 125 nM, which facilitates the ubiquitination and subsequent degradation of the WDR5 protein. The degradation of WDR5 causes the dissociation of the MLL/KMT2A complex from chromatin, leading to reduced levels of H3K4me2. This compound is instrumental in investigating the mechanistic pathways involved in primary leukemia. -
PAK4 Degrader
PAK4-IN-6 is a selective degrader of PAK4 (p21-activated kinase 4), functioning through targeted protein degradation mechanisms. This compound serves as a valuable tool in the synthesis of proteolysis-targeting chimeras (PROTACs) and has potential applications in cancer research and therapeutic development. Its ability to modulate PAK4 levels makes it instrumental in studying signaling pathways and cellular processes involving this kinase. -
PDIA1 PROTAC Degrader
PROTAC PDIA1 Degrader 1 is a PROTAC-based compound designed to selectively target and degrade PDIA1 through the recruitment of the E3 ligase CRBN. It exhibits significant anticancer activity, effectively inhibiting the proliferation of various cancer cell lines. This compound is a valuable tool for researchers investigating the role of PDIA1 in cancer biology and exploring potential therapeutic strategies for targeting this protein. -
KRAS(G12C) Degrader
YF135 is a reversible-covalent PROTAC specifically targeting KRAS(G12C). This compound facilitates the degradation of KRAS(G12C) by linking a potent KRAS G12C inhibitor with a VHL ligand scaffold, effectively promoting the proteasomal pathway via E3 ligase VHL. YF135 significantly reduces phospho-ERK levels, making it a valuable tool for research applications focused on KRAS(G12C)-associated pathways in cancer biology. -
PROTAC PLK4 Degrader
SP27 is a PROTAC that selectively degrades Polo-like kinase 4 (PLK4), exhibiting a DC50 of 19.5 nM. This compound is valuable for investigating the role of PLK4 in cellular processes and is particularly relevant in breast cancer research, enabling studies on potential therapeutic applications and mechanisms of action related to oncogenesis. -
PLK1 PROTAC Degrader
PROTAC PLK1 Degrader-3 is a PLK1-targeted PROTAC that facilitates the degradation of the Polo-like kinase 1 (PLK1) protein through the N-deglycosylation pathway, exhibiting a dissociation constant (Kd) of 2.2 μM. This compound is primarily utilized in research related to non-small cell lung cancer, enabling investigations into targeted protein degradation mechanisms. While the compound shows limited cell penetration, higher concentrations may be necessary to achieve effective degradation outcomes, making it suitable for various biological studies in oncological contexts. -
SMARCA2 PROTAC Degrader
PRT3789 is a selective PROTAC degrader targeting SMARCA2, exhibiting a DC50 of 0.72 nM in HeLa cells for SMARCA2 and 14 nM for SMARCA4. By forming a stable ternary complex with Von Hippel-Lindau (VHL) E3 ligase, PRT3789 facilitates polyubiquitination and subsequent proteasomal degradation of SMARCA2. This compound effectively disrupts the integrity of the SWI/SNF chromatin remodeling complex, leading to the downregulation of oncogenic gene expression, decreased chromatin accessibility, and enhanced expression of genes related to antigen processing and presentation. PRT3789 is applicable in research on SMARCA4-mutated solid tumors, including non-small cell lung cancer, endometrial cancer, and several other malignancies. -
SMARCA2 PROTAC Degrader
NEP202 is a potent SMARCA2 PROTAC degrader that engages the GID4 E3 ligase to facilitate targeted protein degradation. This reagent is valuable for cancer research, enabling the selective degradation of SMARCA2, a key protein implicated in various oncogenic processes. NEP202 offers researchers a powerful tool for studying the role of SMARCA2 in tumor biology and therapeutic responses. -
SMARCA2 Degrader
PROTAC SMARCA2 degrader-32 is a targeted protein degradation agent that selectively degrades SMARCA2 with a DC50 of 1.3 nM. This compound demonstrates significant inhibitory activity against lung cancer cell line NCI-H838, with a GI50 of 34 nM. Its application in research includes studies on the role of SMARCA2 in cancer biology and therapeutic strategies leveraging PROTAC technology for targeted degradation. -
SMARCA2 PROTAC Degrader
PROTAC SMARCA2 degrader-24 is a selective degrader targeting the SMARCA2 protein through a PROTAC mechanism. It exhibits potent biological activity with a DC50 value of less than 0.1 µM in HeLa cells, facilitating effective degradation of SMARCA2. Additionally, it demonstrates lower activity against SMARCA4, with a DC50 greater than 10 μM in the same cellular context. This compound serves as a valuable tool for studying the functional roles of SMARCA2 in various biological processes and disease models. -
SMARCA2 PROTAC Degrader
PROTAC SMARCA2 degrader-22 is a potent proteolysis-targeting chimera (PROTAC) specifically designed to degrade the SMARCA2 protein. It exhibits a degradation efficacy of 94% at a concentration of 100 nM. Additionally, PROTAC SMARCA2 degrader-22 demonstrates effective inhibition of A549 cell proliferation with an EC50 of less than 250 nM, making it a valuable tool for research into cancer biology and therapeutic applications targeting the chromatin remodeling complex. -
PROTAC SMARCA2 Degrader
PROTAC SMARCA2 Degrader-27 is a proteolysis-targeting chimera (PROTAC) that selectively degrades the SMARCA2 protein. By utilizing a VHL ligand, it engages the ubiquitin-proteasome system to induce targeted degradation of SMARCA2, demonstrating significant potential for research in cancer biology. This compound allows for the investigation of SMARCA2's role in oncogenesis and therapeutic resistance, contributing to the development of novel cancer treatments. -
SMARCA2 PROTAC Degrader
PROTAC A515 is a targeted protein degradation agent that selectively degradas the SMARCA2 protein. By promoting the ubiquitination of SMARCA2, it facilitates its subsequent degradation via the proteasome pathway. This compound is valuable for cancer research, allowing for the investigation of SMARCA2's role in tumorigenesis and potential therapeutic applications. -
STING PROTAC Degrader
PROTAC STING degrader-3 is a potent STING PROTAC degrader that operates through the ubiquitin-proteasome pathway, exhibiting a DC50 of 0.62 μM. This compound facilitates STING degradation, resulting in the inhibition of STING/TBK1/NF-κB signaling, thereby exerting notable anti-inflammatory effects. Additionally, PROTAC STING degrader-3 demonstrates renal protective properties and serves as a valuable tool for investigating acute kidney injury (AKI). -
PROTAC STING Degrader
PROTAC STING Degrader-2 is a targeted protein degrader that specifically induces the degradation of the Stimulator of Interferon Genes (STING) through a covalent interaction with STING and an E3 ubiquitin ligase. With a DC50 value of 0.53 μM, this compound facilitates the study of STING's biological functions, particularly in the context of autoinflammatory and autoimmune diseases. This reagent is instrumental for researchers exploring the therapeutic potential and role of STING in immune regulation. -
cGAS PROTAC Degrader
PROTAC cGAS degrader-1 is a selective degrader targeting cGAS through a proteolysis-targeting chimera (PROTAC) mechanism. It effectively induces proteasome-mediated degradation of cGAS, leading to the inhibition of the cGAS signaling pathway and a reduction in double-stranded DNA-induced cGAS activation in both human and mouse cell models. This compound is particularly relevant for research applications in inflammatory diseases such as ulcerative colitis. -
PROTAC IKZF1/3 Degrader
Cemsidomide is a PROTAC degrader targeting IKZF1 and IKZF3, utilizing the ubiquitin ligase pathway. It exhibits potent biological activity with a GI50 of 0.05 nM against NCIH929.1 cells. This compound is primarily employed in the exploration of multiple myeloma (MM) research, facilitating the study of targeted protein degradation in cancer therapeutics. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-3 is a PROTAC-based ligand designed to target and induce the degradation of interleukin-1 receptor-associated kinase 4 (IRAK4) via the von Hippel-Lindau (VHL) E3 ubiquitin ligase. This compound effectively modulates the inflammatory response by selectively degrading IRAK4, making it a valuable tool for exploring therapeutic strategies in inflammatory diseases and immune signaling pathways. Its application in research can provide insights into IRAK4's role in various pathologies, including cancer and autoimmune disorders. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-8 is a targeted protein degradation compound designed to selectively degrade IRAK4, demonstrating an IC50 of 15.5 nM. This reagent effectively induces IRAK4 degradation in THP-1 cells with a DC50 of 1.8 nM. Additionally, PROTAC IRAK4 Degrader-8 inhibits L-6 production in human whole blood and LPS-induced human peripheral blood mononuclear cells, exhibiting IC50 values of 246 nM and 2.2 nM, respectively. This compound is a valuable tool for studying the role of IRAK4 in immune responses and offers potential applications in inflammatory and autoimmune research. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-5 is a Cereblon-based targeted protein degrader specifically designed to induce the degradation of IRAK4. By modulating the ubiquitin-proteasome system, it enhances protein turnover, leading to a decrease in IRAK4 levels. This compound is valuable for research applications focused on inflammation and immune response regulation, enabling the investigation of IRAK4's role in various disease models. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 degrader-12 is a PROTAC compound designed to selectively target and induce the degradation of IRAK4 via the Cereblon E3 ligase pathway. It demonstrates a significant degradation efficacy, achieving a maximum degradation rate of 108.46% in K562 cells with an IC50 of 4.87 nM. This reagent is particularly useful for research applications focused on inflammatory signaling pathways and therapeutic development targeting IRAK4-related diseases. -
IRAK3 PROTAC Degrader
PROTAC IRAK3 degrader-2 is a potent IRAK3 PROTAC degrader with a DC50 of less than or equal to 50 nM. This compound promotes the ubiquitination and subsequent degradation of the IRAK3 protein, making it a valuable tool for studying immune-related diseases. Its unique design incorporates ligands for E3 ligase and a linker configuration, facilitating targeted degradation and aiding research into therapeutic strategies for modulating immune responses.
